How many Tafasitamab clinical trials are there?

50 Tafasitamab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 17 are actively recruiting participants. 5 are marked completed.

Are Tafasitamab clinical trials recruiting in 2026?

Yes — 17 Tafasitamab trials are actively recruiting in 2026, with 113 U.S. sites across 22 states. See the recruiting trials and the per-state site list further down this page.

What conditions is Tafasitamab being studied for?

Tafasitamab is being studied for Diffuse Large B-cell Lymphoma, Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma and 74 more. The trials are grouped by indication on this page.

What phase is Tafasitamab in?

Tafasitamab clinical trials span 4 Phase 3, 24 Phase 2, 4 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.

Who sponsors Tafasitamab clinical trials?

The lead sponsor across the most Tafasitamab trials is Incyte Corporation, with 31 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Tafasitamab Clinical Trials (2026): 50 Studies for Diffuse Large B-cell Lymphoma & Chronic Lymphocytic Leukemia

Creator: Hipa.ai Research
Published: 2026-05-29T17:26:59.642Z

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: June 18, 2026.

50 Tafasitamab clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 32 indications (including Diffuse Large B-cell Lymphoma & Chronic Lymphocytic Leukemia) and 4,528 total planned enrollment. 4 Phase 3 Tafasitamab trials and 24 Phase 2 are listed. 21 Tafasitamab clinical trials are actively recruiting at 113 U.S. sites across 22 states. Most recent activity: NCT06029309 (May 2032).

Where to Participate: All Tafasitamab Trial Sites in the U.S. (113 sites across 22 states)

Every actively recruiting Tafasitamabtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

State	Facility	City	Trial	Map
AZ	Banner University Medical Center - Tucson	Tucson85719	NCT05890352	Map
AZ	University of Arizona Cancer Center-North Campus	Tucson85719	NCT05890352	Map
CA	Tower Cancer Research Foundation	Beverly Hills90211	NCT05890352	Map
CA	City of Hope Comprehensive Cancer Center	Duarte91010	NCT05890352	Map
CA	City of Hope Seacliff	Huntington Beach92648	NCT05890352	Map
CA	City of Hope Antelope Valley	Lancaster93534	NCT05890352	Map
CA	City of Hope at Long Beach Elm	Long Beach90813	NCT05890352	Map
CA	Cedars Sinai Medical Center	Los Angeles90048	NCT05890352	Map
CA	City of Hope Newport Beach	Newport Beach92660	NCT05890352	Map
CA	University of California, San Francisco	San Francisco94143	NCT05351593	Map
CA	City of Hope South Pasadena	South Pasadena91030	NCT05890352	Map
CA	City of Hope South Bay	Torrance90503	NCT05890352	Map
CA	City of Hope Upland	Upland91786	NCT05890352	Map
FL	Holy Cross Hospital	Fort Lauderdale33308	NCT05890352	Map
FL	University of Miami	Miami33136	NCT06029309	Map
FL	Moffitt Cancer Center	Tampa33612	NCT06760156	Map
IL	University of Chicago Comprehensive Cancer Center	Chicago60637	NCT05890352	Map
IL	University of Illinois	Chicago60612	NCT05890352	Map
IL	Carle at The Riverfront	Danville61832	NCT05890352	Map
IL	Carle Physician Group-Effingham	Effingham62401	NCT05890352	Map
IL	Carle Physician Group-Mattoon/Charleston	Mattoon61938	NCT05890352	Map
IL	UC Comprehensive Cancer Center at Silver Cross	New Lenox60451	NCT05890352	Map
IL	University of Chicago Medicine-Orland Park	Orland Park60462	NCT05890352	Map
IL	Memorial Hospital East	Shiloh62269	NCT05890352	Map
IL	Carle Cancer Center	Urbana61801	NCT05890352	Map
IN	Northwest Cancer Center - Main Campus	Crown Point46307	NCT05890352	Map
IN	Northwest Oncology LLC	Dyer46311	NCT05890352	Map
IN	Northwest Cancer Center - Hobart	Hobart46342	NCT05890352	Map
IN	Saint Mary Medical Center	Hobart46342	NCT05890352	Map
IN	Saint Catherine Hospital	Indianapolis46312	NCT05890352	Map
IN	The Community Hospital	Munster46321	NCT05890352	Map
IN	Women's Diagnostic Center - Munster	Munster46321	NCT05890352	Map
IN	Northwest Cancer Center - Valparaiso	Valparaiso46383	NCT05890352	Map
IA	Mercy Hospital	Cedar Rapids52403	NCT05890352	Map
IA	Oncology Associates at Mercy Medical Center	Cedar Rapids52403	NCT05890352	Map
IA	Mercy Medical Center - Des Moines	Des Moines50314	NCT05890352	Map
MI	Trinity Health Saint Joseph Mercy Hospital Ann Arbor	Ann Arbor48106	NCT05890352	Map
MI	Trinity Health IHA Medical Group Hematology Oncology - Brighton	Brighton48114	NCT05890352	Map
MI	Trinity Health Medical Center - Brighton	Brighton48114	NCT05890352	Map
MI	Trinity Health IHA Medical Group Hematology Oncology - Canton	Canton48188	NCT05890352	Map
MI	Trinity Health Medical Center - Canton	Canton48188	NCT05890352	Map
MI	Chelsea Hospital	Chelsea48118	NCT05890352	Map
MI	Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital	Chelsea48118	NCT05890352	Map
MI	Cancer Hematology Centers - Flint	Flint48503	NCT05890352	Map
MI	Genesys Hurley Cancer Institute	Flint48503	NCT05890352	Map
MI	Hurley Medical Center	Flint48503	NCT05890352	Map
MI	University of Michigan Health - Sparrow Lansing	Lansing48912	NCT05890352	Map
MI	Trinity Health Saint Mary Mercy Livonia Hospital	Livonia48154	NCT05890352	Map
MI	Trinity Health Saint Joseph Mercy Oakland Hospital	Pontiac48341	NCT05890352	Map
MI	Huron Gastroenterology PC	Ypsilanti48106	NCT05890352	Map
MI	Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus	Ypsilanti48197	NCT05890352	Map
MN	Essentia Health - Deer River Clinic	Deer River56636	NCT05890352	Map
MN	Essentia Health Cancer Center	Duluth55805	NCT05890352	Map
MN	Essentia Health Hibbing Clinic	Hibbing55746	NCT05890352	Map
MN	Masonic Cancer Center	Minneapolis55455	NCT06792825	Map
MN	Mayo Clinic in Rochester	Rochester55905	NCT05910801	Map
MN	Essentia Health Sandstone	Sandstone55072	NCT05890352	Map
MN	Essentia Health Virginia Clinic	Virginia55792	NCT05890352	Map
MS	University of Mississippi Medical Center	Jackson39216	NCT05890352	Map
MO	Siteman Cancer Center at Saint Peters Hospital	City of Saint Peters63376	NCT05890352	Map
MO	Siteman Cancer Center at West County Hospital	Creve Coeur63141	NCT05890352	Map
MO	Siteman Cancer Center at Christian Hospital	St Louis63136	NCT05890352	Map
MO	Siteman Cancer Center-South County	St Louis63129	NCT05890352	Map
MO	Washington University School of Medicine	St Louis63110	NCT05890352	Map
NJ	Rutgers Cancer Institute of New Jersey	New Brunswick08903	NCT05786040	Map
NY	NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center	New York10032	NCT05890352	Map
NY	University of Rochester	Rochester14642	NCT05890352	Map
NY	Wilmot Cancer Institute at Webster	Webster14580	NCT05890352	Map
NC	University of North Carolina-Hillsborough Campus	Hillsborough27278	NCT05786040	Map
OH	Ohio State University Comprehensive Cancer Center	Columbus43210	NCT05786040	Map
OK	University of Oklahoma Health Sciences Center	Oklahoma City73104	NCT05890352	Map
OR	Providence Newberg Medical Center	Newberg97132	NCT05890352	Map
OR	Providence Willamette Falls Medical Center	Oregon City97045	NCT05890352	Map
OR	OHSU Knight Cancer Institute	Portland97239	NCT05943496	Map
OR	Providence Portland Medical Center	Portland97213	NCT05890352	Map
OR	Providence Saint Vincent Medical Center	Portland97225	NCT05890352	Map
SC	Medical University of South Carolina	Charleston29425	NCT05890352	Map
TX	Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	Houston77030	NCT05890352	Map
TX	Ben Taub General Hospital	Houston77030	NCT05890352	Map
TX	M D Anderson Cancer Center	Houston77030	NCT05615636	Map
TX	MD Anderson Cancer Center	Houston77030	NCT06434363	Map
TX	The University of Texas Health Science Center at Houston	Houston77030	NCT06434363	Map
TX	University of Texas Health Science Center at San Antonio	San Antonio78229	NCT05890352	Map
UT	Huntsman Cancer Institute	Salt Lake City84112	NCT05786040	Map
UT	Huntsman Cancer Institute/University of Utah	Salt Lake City84112	NCT05890352	Map
VA	VCU Massey Cancer Center at Stony Point	Richmond23235	NCT05890352	Map
VA	VCU Massey Comprehensive Cancer Center	Richmond23298	NCT05890352	Map
WA	Fred Hutch/University of Washington Cancer Consortium	Seattle98109	NCT05455697	Map
WI	ThedaCare Regional Cancer Center	Appleton54911	NCT05890352	Map
WI	Duluth Clinic Ashland	Ashland54806	NCT05890352	Map
WI	Aurora Cancer Care-Southern Lakes VLCC	Burlington53105	NCT05890352	Map
WI	Marshfield Medical Center-EC Cancer Center	Eau Claire54701	NCT05890352	Map
WI	Aurora Health Care Germantown Health Center	Germantown53022	NCT05890352	Map
WI	Aurora Cancer Care-Grafton	Grafton53024	NCT05890352	Map
WI	Aurora BayCare Medical Center	Green Bay54311	NCT05890352	Map
WI	Aurora Cancer Care-Kenosha South	Kenosha53142	NCT05890352	Map
WI	Gundersen Lutheran Medical Center	La Crosse54601	NCT05890352	Map
WI	Aurora Bay Area Medical Group-Marinette	Marinette54143	NCT05890352	Map
WI	Marshfield Medical Center-Marshfield	Marshfield54449	NCT05890352	Map
WI	Aurora Cancer Care-Milwaukee	Milwaukee53209	NCT05890352	Map
WI	Aurora Saint Luke's Medical Center	Milwaukee53215	NCT05890352	Map
WI	Aurora Sinai Medical Center	Milwaukee53233	NCT05890352	Map
WI	Marshfield Medical Center - Minocqua	Minocqua54548	NCT05890352	Map
WI	Vince Lombardi Cancer Clinic - Oshkosh	Oshkosh54904	NCT05890352	Map
WI	Aurora Cancer Care-Racine	Racine53406	NCT05890352	Map
WI	Marshfield Medical Center-Rice Lake	Rice Lake54868	NCT05890352	Map
WI	Vince Lombardi Cancer Clinic-Sheboygan	Sheboygan53081	NCT05890352	Map
WI	Marshfield Medical Center-River Region at Stevens Point	Stevens Point54482	NCT05890352	Map
WI	Aurora Medical Center in Summit	Summit53066	NCT05890352	—
WI	Vince Lombardi Cancer Clinic-Two Rivers	Two Rivers54241	NCT05890352	Map
WI	Aurora Cancer Care-Milwaukee West	Wauwatosa53226	NCT05890352	Map
WI	Aurora West Allis Medical Center	West Allis53227	NCT05890352	Map
WI	Marshfield Medical Center - Weston	Weston54476	NCT05890352	Map

Tafasitamab clinical trials at a glance: phase × recruitment status

Phase	recruiting	active not recruiting	completed	terminated	withdrawn	suspended	not yet recruiting	unknown	approved for marketing	Total
Early P1		1								1
P1	1		1			1	1			4
P1/P2	5	3		2	3					13
P2	10	5	2	2	1	1	3			24
P2/P3			1							1
P3	1	3								4
N/A			1					1	1	3

Recruiting Tafasitamab clinical trials (21)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

NCT ID	Title	Phase	Indication	Enrollment	Started
NCT06029309	ZANU-TAFAZanubrutinib and Tafasitamab in Mantle Cell Lymphoma	P1/P2	Mantle Cell Lymphoma	27	May 2024
NCT07126236	REPIFIRResponse-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma	P2	Large B Cell Lymphoma	80	Aug 2025
NCT06792825	HM2023-43HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL	P2	Follicular Lymphoma	65	Aug 2025
NCT07585747	CUREMZL002A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and Lenalidomide	P2	Follicular Lymphoma	27	Apr 2026
NCT06434363	Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders	P1/P2	Autoimmune Disorders	47	Jul 2024
NCT05910801	V-MINDTafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma	P2	Recurrent Mantle Cell Lymphoma	100	Jan 2024
NCT06521255	Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma	P3	DLBCL	244	May 2024
NCT07502872	TPGTPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma	P2	Diffuse Large B Cell Lymphoma	30	May 2026
NCT07582159	Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	P2	Chronic Lymphocytic Leukemia	35	Dec 2026
NCT05366218	Anti-CD19-ALLTafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage Leukemia	P1/P2	ALL, Childhood B-Cell	20	Mar 2023
NCT05890352	Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment	P2	Grade 3b Follicular Lymphoma	227	Sep 2023
NCT06760156	Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym	P2	Large B-cell Lymphoma	28	Mar 2025
NCT05943496	Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma	P1	Chronic Lymphocytic Leukemia	27	Oct 2023
NCT07225439	NHLRituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)	P1	Non Hodgkin Lymphoma	15	Dec 2025
NCT05786040	Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder	P2	Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder	28	Mar 2023
NCT06465433	Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab	P2	Hematologic Malignancies	25	Nov 2022
NCT05615636	A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL	P2	Hodgkin Lymphoma	36	Apr 2023
NCT05455697	Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma	P1/P2	Diffuse Large B-Cell Lymphoma	35	Jan 2023
NCT05583071	MTR²Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL	P2	Non-Hodgkin Lymphoma	20	Aug 2024
NCT05552937	Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCL	P2	DLBCL	50	Sep 2021
NCT05351593	Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma	P1/P2	CNS Lymphoma	35	Jun 2022

Tafasitamab clinical trials by indication

Diffuse Large B-cell Lymphoma (6)

NCT	Acronym	Phase	Status	Title
NCT04824092	frontMIND	P3	active not recruiting	Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients
NCT04981795	realMIND	N/A	completed	realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL
NCT05883709	—	N/A	unknown	A Real-world Study of Tafasitamab in Combination With Lenalidomide in Patients withR/R DLBCL
NCT02763319	B-MIND	P2/P3	completed	A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
NCT02399085	L-MIND	P2	completed	Open Label Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL
NCT04134936	—	P1	completed	Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL

Chronic Lymphocytic Leukemia (4)

NCT	Acronym	Phase	Status	Title
NCT07582159	—	P2	not yet recruiting	Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT05943496	—	P1	recruiting	Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
NCT05718869	—	P2	active not recruiting	Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study
NCT04809467	topMIND	P1/P2	terminated	A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)

DLBCL (4)

NCT	Acronym	Phase	Status	Title
NCT06521255	—	P3	recruiting	Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT04974216	—	P2	active not recruiting	Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older
NCT05552937	—	P2	recruiting	Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCL
NCT04300803	MOR00208	N/A	approved for marketing	Expanded Access Program for Tafasitamab (MOR00208) in R/R DLBCL

Follicular Lymphoma (3)

NCT	Acronym	Phase	Status	Title
NCT06792825	HM2023-43	P2	recruiting	HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL
NCT07585747	CUREMZL002	P2	not yet recruiting	A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and Lenalidomide
NCT04680052	InMIND	P3	active not recruiting	A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.

Diffuse Large B-Cell Lymphoma (3)

NCT	Acronym	Phase	Status	Title
NCT05455697	—	P1/P2	recruiting	Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma
NCT04978584	—	P2	active not recruiting	Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study
NCT05626322	PF-07901801	P1/P2	terminated	Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Diffuse Large B Cell Lymphoma (2)

NCT	Acronym	Phase	Status	Title
NCT07502872	TPG	P2	not yet recruiting	TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
NCT05222555	MINDway	P1/P2	active not recruiting	Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients

Mantle Cell Lymphoma (2)

NCT	Acronym	Phase	Status	Title
NCT06029309	ZANU-TAFA	P1/P2	recruiting	Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma
NCT05788289	—	P2	terminated	A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma

Lymphoma, B-Cell (2)

NCT	Acronym	Phase	Status	Title
NCT04882163	CC-220	P1/P2	withdrawn	Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma
NCT04161248	—	Early P1	active not recruiting	Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

Non Hodgkin Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT07225439	NHL	P1	not yet recruiting	Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT07030699	ECLAT	P2	withdrawn	A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma

Large B Cell Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT07126236	REPIFIR	P2	recruiting	Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma

Large B-cell Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT06760156	—	P2	recruiting	Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym

Non-Hodgkin Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT05583071	MTR²	P2	recruiting	Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL

Autoimmune Disorders (1)

NCT	Acronym	Phase	Status	Title
NCT06434363	—	P1/P2	recruiting	Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders

Chronic Graft Versus Host Disease (1)

NCT	Acronym	Phase	Status	Title
NCT05993611	—	P1	suspended	Allogeneic CD6 Chimeric Antigen Receptor T Regulatory Cells (CD6-CAR Tregs) for the Treatment of Patients With Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation

Recurrent Mantle Cell Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT05910801	V-MIND	P2	recruiting	Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Grade 3b Follicular Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT05890352	—	P2	recruiting	Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT05821088	—	P2	suspended	Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma

Hodgkin Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT05615636	—	P2	recruiting	A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL

B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative (1)

NCT	Acronym	Phase	Status	Title
NCT05453500	—	P2	active not recruiting	Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia

Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder (1)

NCT	Acronym	Phase	Status	Title
NCT05786040	—	P2	recruiting	Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder

ALL, Childhood B-Cell (1)

NCT	Acronym	Phase	Status	Title
NCT05366218	Anti-CD19-ALL	P1/P2	recruiting	Tafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage Leukemia

Large B-Cell Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT05429268	firmMIND	P3	active not recruiting	Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)

Hematologic Malignancies (1)

NCT	Acronym	Phase	Status	Title
NCT06465433	—	P2	recruiting	Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab

CNS Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT05351593	—	P1/P2	recruiting	Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma

Diffuse Large-cell B-cell Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT05328102	DLBCL	P2	terminated	Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)

Relapsed Hematologic Malignancy (1)

NCT	Acronym	Phase	Status	Title
NCT05205252	ARIA	P1/P2	withdrawn	A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.

Marginal Zone Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT04646395	—	P2	active not recruiting	Study of Acalabrutinib and Tafasitamab in MZL Patients

Non Hodgkins Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT04661007	J-MIND	P1/P2	active not recruiting	To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)

Relapsed or Refractory Diffuse Large B-Cell Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT04607772	RR	P1/P2	withdrawn	Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)

Lymphoma, Non-Hodgkin (1)

NCT	Acronym	Phase	Status	Title
NCT03930953	—	P1/P2	active not recruiting	A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

Leukemia, Lymphocytic, Chronic, B-Cell (1)

NCT	Acronym	Phase	Status	Title
NCT02639910	COSMOS	P2	completed	Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi

Tafasitamab pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

Acronym	NCT	Phase	Status	Indication	Enrollment	PubMed
InMIND	NCT04680052	P3	active not recruiting	Follicular Lymphoma	654	PMID 41360064
frontMIND	NCT04824092	P3	active not recruiting	Diffuse Large B-cell Lymphoma	899	PMID 40993016
firmMIND	NCT05429268	P3	active not recruiting	Large B-Cell Lymphoma	82	—
REPIFIR	NCT07126236	P2	recruiting	Large B Cell Lymphoma	80	—
HM2023-43	NCT06792825	P2	recruiting	Follicular Lymphoma	65	—
CUREMZL002	NCT07585747	P2	not yet recruiting	Follicular Lymphoma	27	—
V-MIND	NCT05910801	P2	recruiting	Recurrent Mantle Cell Lymphoma	100	—
TPG	NCT07502872	P2	not yet recruiting	Diffuse Large B Cell Lymphoma	30	—
MTR²	NCT05583071	P2	recruiting	Non-Hodgkin Lymphoma	20	—
ECLAT	NCT07030699	P2	withdrawn	Lymphoma	0	—
L-MIND	NCT02399085	P2	completed	Diffuse Large B-cell Lymphoma	81	PMID 32511983
DLBCL	NCT05328102	P2	terminated	Diffuse Large-cell B-cell Lymphoma	3	—
COSMOS	NCT02639910	P2	completed	Leukemia, Lymphocytic, Chronic, B-Cell	24	PMID 34414843

Terminated and withdrawn Tafasitamab trials (10)

Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.

NCT04882163withdrawnStudy to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma
NCT05993611suspendedAllogeneic CD6 Chimeric Antigen Receptor T Regulatory Cells (CD6-CAR Tregs) for the Treatment of Patients With Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation
NCT05821088suspendedTafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma
NCT07030699withdrawnA Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma
NCT04607772withdrawnStudy of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
NCT05626322terminatedEffects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
NCT04809467terminatedA Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)
NCT05788289terminatedA Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma
NCT05205252withdrawnA Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.
NCT05328102terminatedPhase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)

All Tafasitamab trials (50)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

NCT ID	Acronym	Title	Phase	Status	Enrollment	Sponsor	Started
NCT06029309	ZANU-TAFA	Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma	P1/P2	recruiting	27	Alvaro Alencar, MD	May 2024
NCT07126236	REPIFIR	Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma	P2	recruiting	80	Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea	Aug 2025
NCT06792825	HM2023-43	HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL	P2	recruiting	65	Masonic Cancer Center, University of Minnesota	Aug 2025
NCT05453500		Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia	P2	active not recruiting	32	University of Washington	Mar 2023
NCT07585747	CUREMZL002	A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and Lenalidomide	P2	not yet recruiting	27	Institute of Hematology & Blood Diseases Hospital, China	Apr 2026
NCT06434363		Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders	P1/P2	recruiting	47	M.D. Anderson Cancer Center	Jul 2024
NCT05910801	V-MIND	Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma	P2	recruiting	100	Academic and Community Cancer Research United	Jan 2024
NCT06521255		Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma	P3	recruiting	244	Beijing InnoCare Pharma Tech Co., Ltd.	May 2024
NCT07502872	TPG	TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma	P2	not yet recruiting	30	Brown University	May 2026
NCT07582159		Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	P2	not yet recruiting	35	City of Hope Medical Center	Dec 2026
NCT04882163	CC-220	Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma	P1/P2	withdrawn	0	Celgene	Oct 2021
NCT05366218	Anti-CD19-ALL	Tafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage Leukemia	P1/P2	recruiting	20	University Hospital Tuebingen	Mar 2023
NCT05890352		Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment	P2	recruiting	227	SWOG Cancer Research Network	Sep 2023
NCT04680052	InMIND	A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.	P3	active not recruiting	654	Incyte Corporation	Apr 2021
NCT05993611		Allogeneic CD6 Chimeric Antigen Receptor T Regulatory Cells (CD6-CAR Tregs) for the Treatment of Patients With Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation	P1	suspended	27	City of Hope Medical Center	Feb 2024
NCT04646395		Study of Acalabrutinib and Tafasitamab in MZL Patients	P2	active not recruiting	26	International Extranodal Lymphoma Study Group (IELSG)	Oct 2021
NCT03930953		A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)	P1/P2	active not recruiting	438	Celgene	May 2019
NCT06760156		Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym	P2	recruiting	28	H. Lee Moffitt Cancer Center and Research Institute	Mar 2025
NCT05943496		Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma	P1	recruiting	27	OHSU Knight Cancer Institute	Oct 2023
NCT07225439	NHL	Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)	P1	not yet recruiting	15	Paolo Caimi, MD	Dec 2025
NCT05786040		Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder	P2	recruiting	28	Timothy Voorhees	Mar 2023
NCT05222555	MINDway	Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients	P1/P2	active not recruiting	53	Incyte Corporation	Jul 2022
NCT04824092	frontMIND	Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients	P3	active not recruiting	899	Incyte Corporation	May 2021
NCT06465433		Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab	P2	recruiting	25	Incyte Corporation	Nov 2022
NCT05615636		A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL	P2	recruiting	36	M.D. Anderson Cancer Center	Apr 2023
NCT05455697		Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma	P1/P2	recruiting	35	University of Washington	Jan 2023
NCT04974216		Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older	P2	active not recruiting	71	The Lymphoma Academic Research Organisation	Dec 2021
NCT05583071	MTR²	Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL	P2	recruiting	20	University of Cologne	Aug 2024
NCT05552937		Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCL	P2	recruiting	50	Beijing InnoCare Pharma Tech Co., Ltd.	Sep 2021
NCT05429268	firmMIND	Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)	P3	active not recruiting	82	Incyte Corporation	Dec 2022
NCT04978584		Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study	P2	active not recruiting	62	M.D. Anderson Cancer Center	Mar 2022
NCT05821088		Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma	P2	suspended	37	David Bond, MD	Jun 2023
NCT04661007	J-MIND	To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)	P1/P2	active not recruiting	72	Incyte Biosciences Japan GK	Dec 2020
NCT04161248		Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma	Early P1	active not recruiting	40	Canadian Cancer Trials Group	Sep 2020
NCT05718869		Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study	P2	active not recruiting	26	City of Hope Medical Center	May 2023
NCT05351593		Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma	P1/P2	recruiting	35	James Rubenstein	Jun 2022
NCT07030699	ECLAT	A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma	P2	withdrawn	0	Memorial Sloan Kettering Cancer Center	Aug 2025
NCT04981795	realMIND	realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL	—	completed	102	Incyte Corporation	Sep 2021
NCT04607772	RR	Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)	P1/P2	withdrawn	0	Karyopharm Therapeutics Inc	Nov 2020
NCT05626322	PF-07901801	Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma	P1/P2	terminated	6	Pfizer	Aug 2023
NCT05883709		A Real-world Study of Tafasitamab in Combination With Lenalidomide in Patients withR/R DLBCL	—	unknown	15	Zhao Weili	Jul 2023
NCT04809467	topMIND	A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)	P1/P2	terminated	54	Incyte Corporation	Sep 2021
NCT05788289		A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma	P2	terminated	4	Memorial Sloan Kettering Cancer Center	Mar 2023
NCT02763319	B-MIND	A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)	P2/P3	completed	453	Incyte Corporation	Nov 2016
NCT05205252	ARIA	A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.	P1/P2	withdrawn	0	Epizyme, Inc.	Dec 2021
NCT02399085	L-MIND	Open Label Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL	P2	completed	81	MorphoSys AG	Mar 2016
NCT05328102	DLBCL	Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)	P2	terminated	3	Xencor, Inc.	Apr 2022
NCT04134936		Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL	P1	completed	66	MorphoSys AG	Dec 2019
NCT02639910	COSMOS	Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi	P2	completed	24	MorphoSys AG	Nov 2016
NCT04300803	MOR00208	Expanded Access Program for Tafasitamab (MOR00208) in R/R DLBCL	—	approved for marketing	0	MorphoSys AG	—

Tafasitamab clinical trials: frequently asked questions

How many Tafasitamab clinical trials are there?: 50 Tafasitamab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 17 are actively recruiting participants. 5 are marked completed.
Are Tafasitamab clinical trials recruiting in 2026?: Yes — 17 Tafasitamab trials are actively recruiting in 2026, with 113 U.S. sites across 22 states. See the recruiting trials and the per-state site list further down this page.
What conditions is Tafasitamab being studied for?: Tafasitamab is being studied for Diffuse Large B-cell Lymphoma, Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma and 74 more. The trials are grouped by indication on this page.
What phase is Tafasitamab in?: Tafasitamab clinical trials span 4 Phase 3, 24 Phase 2, 4 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Tafasitamab clinical trials?: The lead sponsor across the most Tafasitamab trials is Incyte Corporation, with 31 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Tafasitamabas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed June 18, 2026.

Related pages on Hipa.ai:

Tafasitamab overview Tafasitamab evidence & publications